Reply

Fleischmann, Roy; Connolly, Seán; Maldonado, Michael A.; Schiff, Michael

doi:10.1002/art.40021

Cited by 3 publications

(13 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The other analyses of radiographic progression by disease activity category for OPERA and all those for SWEFOT used published results, with patient-level data used for confirmation 9,10 . Radiographic progression in AMPLE, for which patient-level data were unavailable, had not been previously reported by category of DAS28-CRP or CRP 16,17 . Thus, it was analyzed here only by category of MBDA score.…”

Section: Association Between Radiographic Progression and Disease Actmentioning

confidence: 98%

“…DAS28-CRP categorical data were obtained from publications that used these categories 10,12 or new analyses of patient-level data, if available 9 . If neither option was possible, the categories used previously for DAS28-CRP in that study, such as the conventional DAS28-ESR categories of remission/low <3.2, moderate 3.2-5.1 and high >5.1, were used here 16,17 . The CRP categories employed here were low 10 mg/L, moderate >10-30 mg/L and high >30 mg/L, to be consistent with prior publications on the MBDA score 10,14 and with the ACR/EULAR definition of Boolean remission (CRP < 10 mg/L) 18 .…”

Section: Clinical Measuresmentioning

confidence: 99%

“…For each cohort included here, MBDA testing had been performed previously on serum samples that had been shipped frozen to the laboratories of Crescendo Bioscience Inc., in South San Francisco, CA, USA, for testing 9,10,12,16,17 . Serum concentrations were determined by electrochemiluminescence-based multiplexed sandwich immunoassays (Meso Scale Discovery, Rockville, MD, USA) for the following 12 biomarkers: vascular cell adhesion molecule 1, epidermal growth factor, vascular endothelial growth factor, interleukin 6, TNF receptor type I, matrix metalloproteinase (MMP) 1, MMP-3, bone glycoprotein 39 (YKL-40), leptin, resistin, serum amyloid A and CRP 5 .…”

Section: Multi-biomarker Disease Activity Score Measurementmentioning

confidence: 99%

“…The methodology of this study was adapted to be aligned with the availability of patient-level data from the selected studies, after they were identified, and to fill gaps in published analyses, where needed. Among the studies identified for the present analyses (Leiden University Early Arthritis Clinic (Leiden) 12,14 , the Optimized Treatment Algorithm for Patients with Early Rheumatoid Arthritis trial (OPERA) 9 , the Swedish Farmacotherapy trial (SWEFOT) 10 and the Abatacept versus Adalimumab Comparison in Biologic-Naive RA Subjects with Background Methotrexate trial (AMPLE) 16,17 , patient-level data were available for cohorts from Leiden, OPERA and SWEFOT. Patient-level data were not available from the AMPLE study.…”

Section: Data Availabilitymentioning

confidence: 99%

“…A review of the literature identified four studies and, from them, five cohorts of at least 100 patients each (total N ¼ 929), that were suitable for inclusion in this analysis (Figure 1). These cohorts were from the Leiden University Early Arthritis Clinic (N ¼ 163) 12,14 , the OPERA trial (N ¼ 164) 9 , the SWEFOT trial (N ¼ 235) 10 and the AMPLE trial (two cohorts: abatacept arm, N ¼ 181 and adalimumab arm, N ¼ 186) 16,17 .…”

Section: Patient Cohortsmentioning

confidence: 99%

See 4 more Smart Citations

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies

Curtis

Brahe

Østergaard

et al. 2019

Current Medical Research and Opinion

View full text Add to dashboard Cite

Objective: To compare the multi-biomarker disease activity (MBDA) score with the DAS28-CRP and CRP for predicting risk of radiographic progression in patients with rheumatoid arthritis. Methods: Published studies of the MBDA score and radiographic progression with 100 patients per cohort were evaluated. Rates of radiographic progression over 1 year were determined across the low/moderate/high categories for MBDA score (low/moderate/high: <30, 30-44, >44), DAS28-CRP (low/ moderate/high: 2.67, >2.67-4.09, >4.09) and CRP (low/moderate/high: 10, >10-30, >30 mg/L), with positive and negative predictive value (PPV, NPV) and relative risk (RR) determined for high vs. not-high (i.e. low and moderate combined) categories. Patient-level data from studies having all three measures was pooled to: (1) determine a combined RR for radiographic progression in the high vs. not-high categories for each measure; and (2) compare the predictive ability of MBDA score vs. DAS28-CRP by comparing the rates of radiographic progression observed in subgroups created by cross-classifying the high and not-high categories of each measure. Results: Five cohorts were identified for inclusion (total N¼929). In each, radiographic progression was more frequent with increasing MBDA scores. Among the three cohorts with requisite data, PPVs were generally similar using categories of MBDA score, DAS28-CRP or CRP but NPVs were greater for MBDA score (93-97%) than DAS28-CRP or CRP (77-87%). RRs for radiographic progression were greater when based on categories of MBDA score than DAS28-CRP or CRP and the combined RR was greater for MBDA score (4.6, p < .0001) than DAS28-CRP (1.7, p ¼ .02) or CRP (1.7, p ¼ .002). For patients cross-classified by MBDA score and DAS28-CRP, high vs. not-high MBDA score significantly predicted radiographic progression independently of DAS28-CRP. Conclusions: High and not-high MBDA scores were associated with increased and low risk, respectively, for radiographic progression over one year. MBDA score was a better predictor of radiographic progression than DAS28-CRP or CRP.

show abstract

Section: Association Between Radiographic Progression and Disease Actmentioning

confidence: 98%

Section: Clinical Measuresmentioning

confidence: 99%

Section: Multi-biomarker Disease Activity Score Measurementmentioning

confidence: 99%

Section: Data Availabilitymentioning

confidence: 99%

Section: Patient Cohortsmentioning

confidence: 99%

See 3 more Smart Citations

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies

Curtis

Brahe

Østergaard

et al. 2019

Current Medical Research and Opinion

View full text Add to dashboard Cite

show abstract

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies

et al. 2021

View full text Add to dashboard Cite

Background The multi-biomarker disease activity (MBDA) test measures 12 serum protein biomarkers to quantify disease activity in RA patients. A newer version of the MBDA score, adjusted for age, sex, and adiposity, has been validated in two cohorts (OPERA and BRASS) for predicting risk for radiographic progression. We now extend these findings with additional cohorts to further validate the adjusted MBDA score as a predictor of radiographic progression risk and compare its performance with that of other risk factors. Methods Four cohorts were analyzed: the BRASS and Leiden registries and the OPERA and SWEFOT studies (total N = 953). Treatments included conventional DMARDs and anti-TNFs. Associations of radiographic progression (ΔTSS) per year with the adjusted MBDA score, seropositivity, and clinical measures were evaluated using linear and logistic regression. The adjusted MBDA score was (1) validated in Leiden and SWEFOT, (2) compared with other measures in all four cohorts, and (3) used to generate curves for predicting risk of radiographic progression. Results Univariable and bivariable analyses validated the adjusted MBDA score and found it to be the strongest, independent predicator of radiographic progression (ΔTSS > 5) compared with seropositivity (rheumatoid factor and/or anti-CCP), baseline TSS, DAS28-CRP, CRP SJC, or CDAI. Neither DAS28-CRP, CDAI, SJC, nor CRP added significant information to the adjusted MBDA score as a predictor, and the frequency of radiographic progression agreed with the adjusted MBDA score when it was discordant with these measures. The rate of progression (ΔTSS > 5) increased from < 2% in the low (1–29) adjusted MBDA category to 16% in the high (45–100) category. A modeled risk curve indicated that risk increased continuously, exceeding 40% for the highest adjusted MBDA scores. Conclusion The adjusted MBDA score was validated as an RA disease activity measure that is prognostic for radiographic progression. The adjusted MBDA score was a stronger predictor of radiographic progression than conventional risk factors, including seropositivity, and its prognostic ability was not significantly improved by the addition of DAS28-CRP, CRP, SJC, or CDAI.

show abstract

Baricitinib

Masche¹

2018

View full text Add to dashboard Cite

show abstract

Reply

Cited by 3 publications

References 6 publications

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies

Predicting risk for radiographic damage in rheumatoid arthritis: comparative analysis of the multi-biomarker disease activity score and conventional measures of disease activity in multiple studies

Validation of the adjusted multi-biomarker disease activity score as a prognostic test for radiographic progression in rheumatoid arthritis: a combined analysis of multiple studies

Baricitinib

Contact Info

Product

Resources

About